NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Nova In Silico

Nova In Silico

Private
LyonHealthcare & Life Scienceshttps://www.novainsilico.ai/

Last Round

Series A

Extension

Feb 16, 2021

Total Funding Raised

$11.5M

Company Overview

Nova In Silico is a health-tech company that develops a clinical trial simulation platform, jinkō, which uses AI and mechanistic disease models to predict drug efficacy and optimize clinical trial development.

Sector

Healthcare & Life Sciences

Verticals

Clinical Trials, Drug Discovery, Medical AI, Synthetic Data, Vertical SaaS

Business Model

B2B

Customer Profile

Subscription SaaS, Services & Consulting, Government Contracts

AI Layer

Infrastructure

Keywords

in silico clinical trialsclinical trial simulationmechanistic disease modelsquantitative systems pharmacologyQSPvirtual patientstrial design optimizationcomputational drug developmentAI drug developmentpatient digital twinmodeling and simulationM&Sdrug development softwareregulatory evidence supportsurrogate modelshealth technology assessmentHTA

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Nova In Silico Comparables

Compare Nova In Silico with similar companies based on industry and business-model similarity.

Nova In Silico comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
QuantHealth
88%
InSilicoTrials Technologies
86%
Unlearn
81%

Nova In Silico Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionFeb 16, 2021
GrantJan 19, 2021
Series AJan 9, 2020

Nova In Silico Investors

Notable investors and investment history

Nova In Silico investors
InvestorRounds
BpifranceGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 27, 2026

    Monthly visitors increased 154% from 2K to 5.2K.

  • Jun 1, 2025

    Monthly visitors increased 30% to 4.3K.

Nova In Silico Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Nova In Silico Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Nova In Silico's valuation, stock price, and market status.

Firmographic Details

HeadquartersLyon
Employee Range61
Year Founded2010
Last FundingFeb 16, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.